Literature DB >> 14594689

Status of pretreatment evaluation, treatment and follow-up regimens for renal cell carcinoma in the Nordic countries.

Søren Mommsen1, Börje Ljungberg, Gudmundur Vikar Einarsson, John Johnsen, Jukka Kallio, Martti Nurmi, Alf Frimann Rosenlund.   

Abstract

OBJECTIVE: One prerequisite for performing multicentre studies is that the clinical handling of the patients must be uniform. We therefore evaluated possible differences in pretreatment evaluation, surgical treatment and follow-up regimes between the Nordic countries and between the different departments that performed nephrectomy due to renal cell carcinoma.
MATERIAL AND METHODS: A questionnaire comprising 21 different questions was sent to all hospitals in the five Nordic countries performing nephrectomy. The questionnaires were returned by 195/226 (86%) departments.
RESULTS: In total, 24% of the departments performed fewer than five tumour nephrectomies per year. The main differences were as follows. I.v. pyelography was never used in Finland in clinics with urologists while preoperative CT scans were performed by most departments and in most countries. Cytology/biopsy examinations were never used in urological clinics in Finland and Iceland in contrast to 31% of urological clinics in Denmark. In Finland, 69% of the departments performed nephrectomy in patients with multiple distant metastases, compared to only 15% in the other Nordic countries. Follow-up after nephrectomy was done in 38% of Danish departments and in 96% of departments in the other Nordic countries.
CONCLUSION: There were evident differences between the urological/surgical departments in the five Nordic countries, especially concerning radiological evaluation, treatment of patients with metastases and postoperative follow-up.

Entities:  

Mesh:

Year:  2003        PMID: 14594689     DOI: 10.1080/00365590310006336

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  1 in total

1.  Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden.

Authors:  Kari Hemminki; Asta Försti; Akseli Hemminki; Börje Ljungberg; Otto Hemminki
Journal:  PLoS One       Date:  2021-06-22       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.